5959-90-0

Basic information

• Product Name: adenosine 5'-triphosphate 5'-adenosine
• Synonyms: adenosine 5'-triphosphate 5'-adenosine
• CAS NO: 5959-90-0
• Molecular Formula: C₂₀H₂₇N₁₀O₁₆P₃
• Molecular Weight: 756.407063
• Mol File: 5959-90-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 1192.8±75.0 °C(Predicted)
• Appearance: /
• Density: 2.53±0.1 g/cm3(Predicted)
• PKA: 0.94±0.50(Predicted)
• CAS DataBase Reference: adenosine 5'-triphosphate 5'-adenosine(CAS DataBase Reference)
• NIST Chemistry Reference: adenosine 5'-triphosphate 5'-adenosine(5959-90-0)
• EPA Substance Registry System: adenosine 5'-triphosphate 5'-adenosine(5959-90-0)

Safety Data

• Hazardous Substances Data: 5959-90-0(Hazardous Substances Data)

Usage

Description

Adenosine 5'-triphosphate 5'-adenosine, also known as Ap5A, is a unique dinucleotide signaling molecule that plays a crucial role in various cellular processes. It is characterized by its ability to bind and modulate the activity of several proteins, including ion channels, kinases, and phosphatases. Ap5A is involved in the regulation of cell growth, apoptosis, and inflammation, making it a significant molecule in the field of biochemistry and molecular biology.

Uses

Used in Pharmaceutical Applications:
Adenosine 5'-triphosphate 5'-adenosine is used as a therapeutic agent for treating pathological calcification and ossification. It helps in the regulation of calcium homeostasis and prevents the abnormal deposition of calcium salts in soft tissues, which can lead to various diseases and complications.
Used in Drug Discovery:
Ap5A is utilized in the identification of potent inhibitors for chromodomain-helicase-DNA-binding protein 1 (CHD1). CHD1 is a chromatin remodeling enzyme that plays a role in gene regulation and has been implicated in various diseases, including cancer. By using Ap5A as a starting point, researchers can develop novel inhibitors that target CHD1, potentially leading to the development of new therapeutic strategies for these diseases.
Used in Research and Development:
Adenosine 5'-triphosphate 5'-adenosine is also used as a research tool in the study of cellular signaling pathways and the development of new drugs targeting various diseases. Its unique properties and ability to interact with multiple proteins make it an invaluable compound for understanding the complex mechanisms underlying cellular processes and for designing targeted therapies.

InChI:InChI=1/2C10H13N5O4.3H3O4P/c2*11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10;3*1-5(2,3)4/h2*2-4,6-7,10,16-18H,1H2,(H2,11,12,13);3*(H3,1,2,3,4)/t2*4-,6-,7-,10-;;;/m11.../s1

Upstream product

• 61-19-8 5'-adenosine monophosphate 
• 20816-58-4 adenosine 5'-phosphorimidazolide 
• 58-64-0 adenosine 5'-diphosphate 
• 1350980-53-8 C₂₆H₄₁N₁₀O₁₅P₃S 
• 56-65-5 ATP 
• 4691-96-7 adenosine 5'-triphosphate sodium salt 
• 35985-27-4 lysyl adenylate 

Downstream Products

• 60-92-4 cAMP 
• 61-19-8 5'-adenosine monophosphate 
• 58-64-0 adenosine 5'-diphosphate 
• 66224-66-6 adenine 
• 4578-31-8 adenosine-5'-monophosphate disodium salt 

Relevant articles and documents

Isolation and identification of diadenosine 5′,5?-P 1,P4-tetraphosphate binding proteins using magnetic bio-panning

We report the development of a synthetic, biotin-conjugated diadenosine tetraphosphate (Ap4A)-'molecular hook' attached to magnetic beads enabling the isolation of Ap4A-binding proteins from bacterial cells or mammalian tissue lysates. Characterisation and identification of isolated binding proteins is performed sequentially by mass spectrometry. The observation of positive controls suggests that these newly observed proteins are putative Ap4A-binding partners, and we have expectations that others can be found with further technical improvements in our methods.

NEW USES OF DINUCLEOTIDE POLYPHOSPHATE DERIVATIVES

The present invention provides the use of analogues and derivatives of dinucleoside polyphosphates with formula (I) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in one or more of: the treatment of ischemia, inducing ischemic tolerance, modulating cerebral ischemia, to delay the onset of a hypoxic depolarisation stage when ischemic events are initiated; as a neurological protection agent; as a tissue protection agent; the treatment of pain; and the treatment of inflammation, wherein X, is selected from wherein X1 and X2 are independently selected from H, Cl, Br and F; each Y is independently selected from S and O; each Z is independently selected from -CX3X4-,-NH-,-O- ; wherein X3 and X4 are selected from H, CI, Br and F; B1 and B2 are independently selected from adenine, guanine, xanthine, thymine, uracil, cytosine and inosine; S1 and S2 are independently selected from ribose, open chain ribose, 2'-deoxyribose, 3'deoxyribose and arabinofuranoside. V is selected from 0, 1 , 2, 3, 4 and 5; W is selected from 0, 1 , 2, 3, 4 and 5; and V plus W is an integer from 2 to 6.

Synthesis and reactions of nucleoside 5'-diphosphate imidazolide. A nonenzymatic capping agent for 5'-monophosphorylated oligoribonucleotides in aqueous solution

We have synthesized adenosine and 7-methylguanosine 5'-diphosphate imidazolides from imidazole and the corresponding nucleoside 5'-diphosphates. The phosphorimidazolide bond of the compounds was susceptible to hydrolysis and hydrolyzed gradually in neutral aqueous solution, but it was more stable than that of the corresponding imidazolides of nucleoside 5'-monophosphate. The 7-methylguanosine 5'-diphosphate imidazolide reacted with guanosine 5'- monophosphate or 5' monophosphorylated oligoribonucleotides in neutral aqueous solution in the presence of an Mn2- ion catalyst converting to the cap portion of mRNA or the capped m7Gppp-oligoribonucleotides in substantial yields. The condensation reaction of adenosine 5'-diphosphate imidazolide with adenosine 5'-monophosphate took place similarly in neutral aqueous solution by a divalent metal ion-catalyst such as Mg2+ or Mn2+, yielding diadenosine 5',5'-triphosphate.